T. Mohamed and P. P.N. Rao Pages 4299 - 4320 ( 22 )
Alzheimer's disease (AD) is a highly complex and rapidly progressive neurodegenerative disorder characterized by the systemic collapse of cognitive function and formation of dense amyloid plaques and neurofibrillary tangles. AD pathology is derived from the cholinergic, amyloid and tau hypotheses, respectively. Current pharmacotherapy with known anti-cholinesterases, such as Aricept® and Exelon®, only offer symptomatic relief without any disease-modifying effects. It is now clear that in order to prevent the rapid progression of AD, new therapeutic treatments should target multiple AD pathways as opposed to the traditional “one drug, one target” approach. This review will focus on the recent advances in medicinal chemistry aimed at the development of small molecule therapies that target various AD pathological routes such as the cholinesterases (AChE and BuChE), amyloidogenic secretases (β/γ- secretase), amyloid-β aggregation, tau phosphorylation and fibrillation and metal-ion redox/reactive oxygen species (ROS). Some notable ring templates will be discussed along with their structure-activity relationship (SAR) data and their multiple modes of action. These emerging trends signal a paradigm shift in anti-AD therapies aimed at the development of multifunctional small molecules as diseasemodifying agents (DMAs).
Alzheimer's disease,amyloid plaques,amyloid precursor protein,cholinesterase,disease-modifying agents,neurofibrillary tangles,reactive oxygen species,α/β/γ-secretase,tau protein,AD
, School of Pharmacy, University of Waterloo, Health Sciences Campus, 200 University Ave. West, Waterloo, Ontario, CANADA N2L 3G1. Office: PHR 5002, Canada.